Health Trials

Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer

A Phase 2 Multi-center Open-label Trial of nab-Sirolimus in Combination with Letrozole in Advanced or Recurrent Endometrioid Endometrial Cancer

Participants needed: 29
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Aadi Bioscience, Inc.Updated: Nov 13, 2025Locations: 9
Eligibility criteria

Patients must have clinically confirmed advanced or recurrent endometrioid endom... [+23]

Prior treatment with an mTOR inhibitor, including nab-sirolimus. [+12]

Read more
Status: Recruiting

Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment

This is a phase 1, multi-center, open-label, dose-escalation study of nab-sirolimus in adult patients with locally advanced or metastatic solid tumors and moderate hepatic impairment or normal hepatic function.

Participants needed: 28
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Aadi Bioscience, Inc.Updated: Nov 13, 2025Locations: 2
Eligibility criteria

For All Patients [+13]

Received prior treatment with an mTOR inhibitor within 4 weeks prior to first do... [+18]

Read more
Status: Recruiting

Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors

A Phase 2 multi-center, open-label, single arm study of nab-sirolimus in patients with well-differentiated neuroendocrine tumors (NETs) of the gastrointestinal tract, lung, or pancreas who have not received prior treatment with mTOR inhibitors

Participants needed: 21
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Aadi Bioscience, Inc.Updated: Jul 16, 2024Locations: 4
Eligibility criteria

Patients with functional or non-functional, well-differentiated, locally advance... [+21]

Prior treatment with mTOR inhibitors including nab-sirolimus [+12]

Read more